Following today's meeting with the FDA concerning IBT's live biotherapeutic product, IBT has decided to pursue an accelerated approval pathway for IBP-9414. The FDA's Accelerated Approval Program allo ...

A powerful new antibiotic candidate has been hiding in plain sight inside a well known bacterial compound, and in early lab ...

Biphenomycins, natural products derived from bacteria, show excellent antimicrobial activity, but have long remained out of ...

An international research team has uncovered a surprising ally in the fight against insulin resistance and type 2 diabetes: a ...

New research suggests habitual nose picking could damage the nasal lining, allowing bacteria to enter the brain via the ...

A disease that has stalked humanity for millennia may have finally met its match. Mycobacterium tuberculosis, the pathogen ...

A Swediah biopharma company developing live biotherapeutic products for diseases affecting premature infants, led by IBP-9414 ...

Synergy graph illustrating the efficacy of the dual inhibition Mtb treatment strategy. (Credit: Campbell lab) Tuberculosis is both curable and ...

In several disease conditions, including infections and cancers, innate immune activation and nutrient scarcity occur ...

The PrIMAVeRa project develops a platform to evaluate how mAbs can combat AMR by reducing antibiotic use and providing ...